New Multi-Protein Blood Test Accurately Detects Late-Stage Alzheimer's Disease
Researchers said a seven-protein blood panel improved staging of late-stage Alzheimer’s disease and outperformed p-tau217 alone in predicting advanced tau pathology.
- Researchers at the University of Gothenburg identified a 7-protein blood panel that significantly improves Alzheimer's staging, offering a more accessible alternative to traditional PET scans.
- Historically, Alzheimer's diagnosis relied on late-stage cognitive changes or specialized PET scans, which limited accessibility for many patients seeking earlier detection.
- Scientists utilized machine learning to analyze data from a novel immunoassay platform that measures more than 120 inflammation and neuronal markers in a single blood sample.
- Complementing diagnostic advancements, researchers at Duke Health found approximately 80% of patients receiving the FDA-approved therapy lecanemab remained on treatment for at least one year.
- To enhance safety, the team piloted an artificial intelligence tool to detect Amyloid Related Imaging Abnormalities earlier, strengthening patient monitoring as they expand its use soon.
14 Articles
14 Articles
Domestic introduction of Alzheimer's disease diagnostic blood test within sight; p-tau confirms amyloid changes in the brain; following Rekembi, the approval process for Kisunra shifts from 'symptom treatment' to 'inhibition of disease progression'. The diagnosis and treatment methods of Alzheimer's disease, a long-standing challenge in the medical community...
What’s next for Alzheimer’s blood tests? Experts predict the future of dementia detection
The Alzheimer’s blood test has been climbing headlines as families, patients and clinicians ask whether a simple draw can replace lumbar punctures and PET scans, and whether it can catch the disease before symptoms take hold. Recent studies suggest the…
How safe is the new Alzheimer's drug?
A real-world study provides new insights into the safety of a new Alzheimer’s disease drug. As new Alzheimer’s drugs move from clinical trials into everyday care, families are asking whether these treatments are safe, how long patients can stay on them, and whether they truly slow the disease outside tightly controlled studies. Researchers at Duke Health studied more than 230 patients treated with lecanemab, a new FDA-approved therapy (known as …
A broader panel of protein markers could lead to better blood tests for Alzheimer's
In Alzheimer's disease, amyloid plaques form in the brain, followed by threadlike structures made of the protein tau. Both changes have toxic effects on the brain's nerve cells years before dementia symptoms appear. Historically, diagnosis has primarily relied on cognitive changes, which manifest at a later stage of the disease. Biomarker-based diagnostics were initially limited to specialized clinics capable of performing cerebrospinal fluid sa…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
